| Protein | Potency Measurements | Inhibition Measurements | Activation Measurements | Drugs |
|---|
| RAR-related orphan receptor gamma | 8 | 0 | 0 | 8 |
| TDP1 protein | 7 | 0 | 0 | 7 |
| estrogen nuclear receptor alpha | 9 | 0 | 0 | 9 |
| Liver carboxylesterase 1 | 0 | 0 | 0 | 1 |
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | 2 | 0 | 0 | 2 |
| Chain A, Cruzipain | 1 | 0 | 0 | 1 |
| interleukin 8 | 1 | 0 | 0 | 1 |
| pregnane X receptor | 1 | 0 | 0 | 1 |
| hypoxia-inducible factor 1 alpha subunit | 3 | 0 | 0 | 3 |
| SMAD family member 2 | 1 | 0 | 0 | 1 |
| SMAD family member 3 | 1 | 0 | 0 | 1 |
| GLI family zinc finger 3 | 4 | 0 | 0 | 4 |
| AR protein | 5 | 0 | 0 | 5 |
| hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | 1 | 0 | 0 | 1 |
| thyroid stimulating hormone receptor | 4 | 0 | 0 | 4 |
| estrogen receptor 2 (ER beta) | 3 | 0 | 0 | 3 |
| nuclear receptor subfamily 1, group I, member 3 | 5 | 0 | 0 | 5 |
| progesterone receptor | 4 | 0 | 0 | 4 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | 4 | 0 | 0 | 4 |
| glucocorticoid receptor [Homo sapiens] | 3 | 0 | 0 | 3 |
| retinoic acid nuclear receptor alpha variant 1 | 6 | 0 | 0 | 6 |
| retinoid X nuclear receptor alpha | 5 | 0 | 0 | 5 |
| estrogen-related nuclear receptor alpha | 7 | 0 | 0 | 7 |
| farnesoid X nuclear receptor | 4 | 0 | 0 | 4 |
| pregnane X nuclear receptor | 5 | 0 | 0 | 5 |
| G | 2 | 0 | 0 | 2 |
| peroxisome proliferator-activated receptor delta | 4 | 0 | 0 | 4 |
| peroxisome proliferator activated receptor gamma | 2 | 0 | 0 | 2 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | 4 | 0 | 0 | 4 |
| euchromatic histone-lysine N-methyltransferase 2 | 4 | 0 | 0 | 4 |
| aryl hydrocarbon receptor | 4 | 0 | 0 | 4 |
| thyroid stimulating hormone receptor | 4 | 0 | 0 | 4 |
| activating transcription factor 6 | 4 | 0 | 0 | 4 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | 3 | 0 | 0 | 3 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | 5 | 0 | 0 | 5 |
| Histone H2A.x | 2 | 0 | 0 | 2 |
| Caspase-7 | 2 | 0 | 0 | 2 |
| cellular tumor antigen p53 isoform a | 2 | 0 | 0 | 2 |
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | 1 | 0 | 0 | 1 |
| thyroid hormone receptor beta isoform a | 2 | 0 | 0 | 2 |
| potassium voltage-gated channel subfamily H member 2 isoform d | 5 | 0 | 0 | 5 |
| caspase-3 | 2 | 0 | 0 | 2 |
| thyroid hormone receptor beta isoform 2 | 6 | 0 | 0 | 6 |
| heat shock protein beta-1 | 3 | 0 | 0 | 3 |
| mitogen-activated protein kinase 1 | 4 | 0 | 0 | 4 |
| nuclear factor NF-kappa-B p105 subunit isoform 1 | 1 | 0 | 0 | 1 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | 4 | 0 | 0 | 4 |
| geminin | 5 | 0 | 0 | 5 |
| peripheral myelin protein 22 | 2 | 0 | 0 | 2 |
| lethal factor (plasmid) | 3 | 0 | 0 | 3 |
| lamin isoform A-delta10 | 3 | 0 | 0 | 3 |
| Voltage-dependent calcium channel gamma-2 subunit | 2 | 0 | 0 | 2 |
| Interferon beta | 2 | 0 | 0 | 2 |
| HLA class I histocompatibility antigen, B alpha chain | 2 | 0 | 0 | 2 |
| Cellular tumor antigen p53 | 4 | 0 | 0 | 4 |
| Androgen receptor | 0 | 2 | 0 | 2 |
| Glutamate receptor 2 | 2 | 0 | 0 | 2 |
| Nuclear receptor ROR-gamma | 2 | 0 | 0 | 2 |
| Inositol hexakisphosphate kinase 1 | 2 | 0 | 0 | 2 |
| cytochrome P450 2C9, partial | 2 | 0 | 0 | 2 |
| Multidrug resistance-associated protein 4 | 0 | 6 | 0 | 7 |
| Solute carrier organic anion transporter family member 1A4 | 0 | 0 | 0 | 1 |
| Solute carrier organic anion transporter family member 1A5 | 0 | 0 | 0 | 1 |
| Steryl-sulfatase | 0 | 0 | 0 | 1 |
| Multidrug resistance-associated protein 1 | 0 | 0 | 0 | 1 |
| Solute carrier organic anion transporter family member 1A1 | 0 | 0 | 0 | 1 |
| Solute carrier organic anion transporter family member 1A2 | 0 | 0 | 0 | 1 |
| Solute carrier organic anion transporter family member 1A3 | 0 | 0 | 0 | 1 |
| G-protein coupled bile acid receptor 1 | 0 | 0 | 1 | 1 |
| ATP-binding cassette sub-family C member 11 | 0 | 0 | 0 | 1 |
| Solute carrier organic anion transporter family member 1B3 | 0 | 0 | 0 | 1 |
| Solute carrier family 22 member 11 | 0 | 0 | 0 | 1 |
| Solute carrier organic anion transporter family member 1A1 | 0 | 0 | 0 | 1 |
| Solute carrier organic anion transporter family member 1B2 | 0 | 0 | 0 | 1 |
| Solute carrier organic anion transporter family member 1B1 | 0 | 0 | 0 | 1 |
| Chain A, Beta-lactamase | 3 | 0 | 0 | 3 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | 4 | 0 | 0 | 4 |
| Chain A, Ferritin light chain | 1 | 0 | 0 | 1 |
| bromodomain adjacent to zinc finger domain 2B | 4 | 0 | 0 | 4 |
| serine-protein kinase ATM isoform a | 1 | 0 | 0 | 1 |
| chromobox protein homolog 1 | 2 | 0 | 0 | 2 |
| lethal(3)malignant brain tumor-like protein 1 isoform I | 1 | 0 | 0 | 1 |
| cytochrome P450 3A4 isoform 1 | 2 | 0 | 0 | 2 |
| Gamma-aminobutyric acid receptor subunit pi | 2 | 0 | 0 | 2 |
| Gamma-aminobutyric acid receptor subunit beta-1 | 2 | 0 | 0 | 2 |
| Gamma-aminobutyric acid receptor subunit delta | 2 | 0 | 0 | 2 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | 2 | 0 | 0 | 2 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | 2 | 0 | 0 | 2 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | 2 | 0 | 0 | 2 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | 2 | 0 | 0 | 2 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | 2 | 0 | 0 | 2 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | 2 | 0 | 0 | 2 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | 2 | 0 | 0 | 2 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | 2 | 0 | 0 | 2 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | 2 | 0 | 0 | 2 |
| Gamma-aminobutyric acid receptor subunit beta-3 | 2 | 0 | 0 | 2 |
| Gamma-aminobutyric acid receptor subunit beta-2 | 2 | 0 | 0 | 2 |
| GABA theta subunit | 2 | 0 | 0 | 2 |
| Gamma-aminobutyric acid receptor subunit epsilon | 2 | 0 | 0 | 2 |
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | 4 | 0 | 0 | 4 |
| Chain A, Putative fructose-1,6-bisphosphate aldolase | 1 | 0 | 0 | 1 |
| phosphopantetheinyl transferase | 2 | 0 | 0 | 2 |
| Fumarate hydratase | 2 | 0 | 0 | 2 |
| GLS protein | 3 | 0 | 0 | 3 |
| aldehyde dehydrogenase 1 family, member A1 | 2 | 0 | 0 | 2 |
| EWS/FLI fusion protein | 4 | 0 | 0 | 4 |
| polyprotein | 2 | 0 | 0 | 2 |
| ATP-binding cassette sub-family C member 3 | 0 | 5 | 0 | 5 |
| Bile salt export pump | 0 | 1 | 0 | 1 |
| Bile salt export pump | 0 | 5 | 0 | 5 |
| Aldo-keto reductase family 1 member C3 | 0 | 1 | 0 | 1 |
| Aldo-keto reductase family 1 member C2 | 0 | 1 | 0 | 1 |
| Inositol monophosphatase 1 | 2 | 0 | 0 | 2 |
| Aldo-keto reductase family 1 member C1 | 0 | 1 | 0 | 1 |
| Canalicular multispecific organic anion transporter 1 | 0 | 5 | 0 | 5 |
| endonuclease IV | 2 | 0 | 0 | 2 |
| GALC protein | 1 | 0 | 0 | 1 |
| Smad3 | 3 | 0 | 0 | 3 |
| 67.9K protein | 2 | 0 | 0 | 2 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | 2 | 0 | 0 | 2 |
| lysosomal alpha-glucosidase preproprotein | 2 | 0 | 0 | 2 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | 1 | 0 | 0 | 1 |
| peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | 1 | 0 | 0 | 1 |
| DNA polymerase iota isoform a (long) | 1 | 0 | 0 | 1 |
| DNA polymerase kappa isoform 1 | 1 | 0 | 0 | 1 |
| survival motor neuron protein isoform d | 3 | 0 | 0 | 3 |
| Carbonic anhydrase 12 | 0 | 1 | 1 | 3 |
| Carbonic anhydrase 1 | 0 | 1 | 1 | 3 |
| Carbonic anhydrase 2 | 0 | 1 | 1 | 3 |
| Carbonic anhydrase 3 | 0 | 1 | 1 | 2 |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | 0 | 2 | 0 | 2 |
| Carbonic anhydrase 4 | 0 | 1 | 1 | 3 |
| Carbonic anhydrase 6 | 0 | 1 | 1 | 3 |
| Carbonic anhydrase 5A, mitochondrial | 0 | 1 | 1 | 3 |
| Carbonic anhydrase 7 | 0 | 1 | 1 | 3 |
| Carbonic anhydrase 9 | 0 | 1 | 1 | 3 |
| Carbonic anhydrase 13 | 0 | 0 | 1 | 1 |
| Carbonic anhydrase 13 | 0 | 1 | 0 | 2 |
| Carbonic anhydrase 14 | 0 | 1 | 1 | 3 |
| Carbonic anhydrase 5B, mitochondrial | 0 | 1 | 1 | 3 |
| 5-hydroxytryptamine receptor 3E | 0 | 2 | 0 | 2 |
| vitamin D3 receptor isoform VDRA | 2 | 0 | 0 | 2 |
| ubiquitin carboxyl-terminal hydrolase 2 isoform a | 2 | 0 | 0 | 2 |
| FAD-linked sulfhydryl oxidase ALR | 0 | 0 | 0 | 1 |
| 5-hydroxytryptamine receptor 4 | 0 | 4 | 0 | 4 |
| 5-hydroxytryptamine receptor 3B | 0 | 2 | 0 | 2 |
| Muscarinic acetylcholine receptor M2 | 0 | 3 | 0 | 3 |
| Muscarinic acetylcholine receptor M4 | 0 | 4 | 0 | 4 |
| ATP-dependent translocase ABCB1 | 0 | 0 | 0 | 2 |
| Cytochrome P450 3A4 | 0 | 3 | 0 | 3 |
| 5-hydroxytryptamine receptor 1A | 0 | 3 | 3 | 6 |
| 5-hydroxytryptamine receptor 2C | 0 | 4 | 0 | 4 |
| Muscarinic acetylcholine receptor M5 | 0 | 4 | 0 | 4 |
| Alpha-2A adrenergic receptor | 0 | 5 | 0 | 5 |
| Muscarinic acetylcholine receptor M1 | 0 | 3 | 1 | 4 |
| Glucose-6-phosphate 1-dehydrogenase | 0 | 1 | 0 | 1 |
| Angiotensin-converting enzyme | 0 | 5 | 0 | 5 |
| D(2) dopamine receptor | 0 | 7 | 0 | 8 |
| 5-hydroxytryptamine receptor 2A | 0 | 5 | 0 | 5 |
| Alpha-1B adrenergic receptor | 0 | 3 | 0 | 3 |
| Alpha-2B adrenergic receptor | 0 | 5 | 0 | 5 |
| Alpha-2C adrenergic receptor | 0 | 5 | 0 | 5 |
| D | 0 | 3 | 0 | 3 |
| D(3) dopamine receptor | 0 | 2 | 0 | 2 |
| 5-hydroxytryptamine receptor 1A | 0 | 3 | 0 | 3 |
| Alpha-2B adrenergic receptor | 0 | 3 | 0 | 3 |
| Muscarinic acetylcholine receptor M3 | 0 | 5 | 0 | 5 |
| D(1A) dopamine receptor | 0 | 5 | 0 | 5 |
| D(4) dopamine receptor | 0 | 4 | 0 | 4 |
| Alpha-2C adrenergic receptor | 0 | 3 | 0 | 3 |
| UDP-glucuronosyltransferase 1A4 | 0 | 0 | 0 | 1 |
| Alpha-2A adrenergic receptor | 0 | 3 | 0 | 3 |
| Alpha-1D adrenergic receptor | 0 | 3 | 0 | 3 |
| Sodium-dependent noradrenaline transporter | 0 | 1 | 0 | 1 |
| Adenosine receptor A1 | 0 | 1 | 0 | 1 |
| Alpha-1D adrenergic receptor | 0 | 6 | 0 | 6 |
| 5-hydroxytryptamine receptor 2A | 0 | 6 | 0 | 7 |
| 5-hydroxytryptamine receptor 2C | 0 | 5 | 0 | 5 |
| D(4) dopamine receptor | 0 | 1 | 0 | 1 |
| 5-hydroxytryptamine receptor 2B | 0 | 4 | 0 | 4 |
| Histamine H1 receptor | 0 | 2 | 0 | 2 |
| Sodium-dependent serotonin transporter | 0 | 4 | 0 | 4 |
| 5-hydroxytryptamine receptor 7 | 0 | 4 | 0 | 4 |
| Alpha-1A adrenergic receptor | 0 | 5 | 0 | 5 |
| Histamine H1 receptor | 0 | 5 | 1 | 7 |
| Alpha-1B adrenergic receptor | 0 | 4 | 0 | 4 |
| D(3) dopamine receptor | 0 | 5 | 0 | 5 |
| 5-hydroxytryptamine receptor 2B | 0 | 5 | 0 | 5 |
| Alpha-1A adrenergic receptor | 0 | 3 | 0 | 3 |
| 5-hydroxytryptamine receptor 3A | 0 | 2 | 0 | 2 |
| 5-hydroxytryptamine receptor 6 | 0 | 4 | 0 | 4 |
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | 0 | 3 | 0 | 3 |
| Spike glycoprotein | 3 | 0 | 0 | 3 |
| D(2) dopamine receptor | 0 | 5 | 0 | 5 |
| Disintegrin and metalloproteinase domain-containing protein 17 | 2 | 0 | 0 | 2 |
| Potassium voltage-gated channel subfamily H member 2 | 0 | 9 | 0 | 9 |
| Sigma non-opioid intracellular receptor 1 | 0 | 1 | 0 | 1 |
| Transporter | 0 | 3 | 0 | 3 |
| Nuclear receptor subfamily 3 group C member 3 | 0 | 5 | 0 | 5 |
| 5-hydroxytryptamine receptor 3D | 0 | 2 | 0 | 2 |
| 5-hydroxytryptamine receptor 3C | 0 | 2 | 0 | 2 |
| Transporter | 0 | 2 | 0 | 2 |
| Solute carrier family 22 member 1 | 0 | 1 | 0 | 1 |
| Acetylcholinesterase | 0 | 1 | 0 | 1 |
| Delta-type opioid receptor | 0 | 1 | 0 | 1 |
| Kappa-type opioid receptor | 0 | 0 | 1 | 1 |
| Mu-type opioid receptor | 0 | 1 | 0 | 1 |
| Kappa-type opioid receptor | 0 | 1 | 0 | 1 |
| Mu-type opioid receptor | 0 | 1 | 1 | 2 |
| Delta-type opioid receptor | 0 | 0 | 1 | 1 |
| Kappa-type opioid receptor | 0 | 1 | 0 | 1 |
| Kappa-type opioid receptor | 0 | 0 | 1 | 1 |
| Mu-type opioid receptor | 0 | 0 | 1 | 1 |
| Sigma non-opioid intracellular receptor 1 | 0 | 1 | 0 | 1 |
| Sodium channel protein type 1 subunit alpha | 0 | 1 | 0 | 1 |
| Sodium channel protein type 2 subunit alpha | 0 | 1 | 0 | 1 |
| Sodium channel protein type 3 subunit alpha | 0 | 1 | 0 | 1 |
| Vasopressin V2 receptor | 0 | 1 | 1 | 2 |
| Oxytocin receptor | 0 | 2 | 2 | 4 |
| Vasopressin V1a receptor | 0 | 1 | 0 | 1 |
| Vasopressin V1a receptor | 0 | 2 | 1 | 3 |
| Vasopressin V1b receptor | 0 | 1 | 1 | 2 |
| Vasopressin V1b receptor | 0 | 1 | 0 | 1 |
| Oxytocin receptor | 0 | 1 | 0 | 1 |
| Oxytocin receptor | 0 | 0 | 1 | 1 |
| Vasopressin V2 receptor | 0 | 1 | 0 | 1 |
| IDH1 | 2 | 0 | 0 | 2 |
| Angiotensin-converting enzyme | 0 | 1 | 0 | 1 |
| Chain A, ATP-DEPENDENT DNA HELICASE Q1 | 1 | 0 | 0 | 1 |
| acetylcholinesterase | 3 | 0 | 0 | 3 |
| glp-1 receptor, partial | 1 | 0 | 0 | 1 |
| NFKB1 protein, partial | 1 | 0 | 0 | 1 |
| Microtubule-associated protein tau | 2 | 0 | 0 | 2 |
| Thrombopoietin | 1 | 0 | 0 | 1 |
| apical membrane antigen 1, AMA1 | 1 | 0 | 0 | 1 |
| caspase 7, apoptosis-related cysteine protease | 1 | 0 | 0 | 1 |
| NADPH oxidase 1 | 0 | 1 | 0 | 1 |
| regulator of G-protein signaling 4 | 1 | 0 | 0 | 1 |
| cytochrome P450 2D6 | 3 | 0 | 0 | 3 |
| glucocerebrosidase | 1 | 0 | 0 | 1 |
| Snq2p | 0 | 0 | 0 | 1 |
| caspase-3 | 1 | 0 | 0 | 1 |
| heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) | 1 | 0 | 0 | 1 |
| cytochrome P450 2D6 isoform 1 | 2 | 0 | 0 | 2 |
| NPC intracellular cholesterol transporter 1 precursor | 1 | 0 | 0 | 1 |
| peripheral myelin protein 22 isoform 1 | 2 | 0 | 0 | 2 |
| cytochrome P450 2C19 precursor | 2 | 0 | 0 | 2 |
| D(1A) dopamine receptor | 1 | 0 | 0 | 1 |
| transcriptional regulator ERG isoform 3 | 2 | 0 | 0 | 2 |
| ubiquitin-conjugating enzyme E2 N | 0 | 1 | 0 | 1 |
| atrial natriuretic peptide receptor 2 precursor | 1 | 0 | 0 | 1 |
| ras-related protein Rab-9A | 1 | 0 | 0 | 1 |
| protein AF-9 isoform a | 0 | 0 | 0 | 1 |
| serine/threonine-protein kinase mTOR isoform 1 | 1 | 0 | 0 | 1 |
| bcl-2-related protein A1 | 0 | 1 | 0 | 1 |
| nuclear receptor ROR-gamma isoform 1 | 2 | 0 | 0 | 2 |
| Vpr | 1 | 0 | 0 | 1 |
| M-phase phosphoprotein 8 | 1 | 0 | 0 | 1 |
| transient receptor potential cation channel subfamily V member 1 | 1 | 0 | 0 | 1 |
| muscarinic acetylcholine receptor M1 | 2 | 0 | 0 | 2 |
| DNA repair protein RAD52 homolog isoform a | 0 | 0 | 0 | 1 |
| neuropeptide S receptor isoform A | 1 | 0 | 0 | 1 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | 1 | 0 | 0 | 1 |
| Aldehyde oxidase 1 | 0 | 1 | 0 | 1 |
| Retinal dehydrogenase 1 | 0 | 1 | 0 | 1 |
| Integrin beta-3 | 1 | 0 | 0 | 1 |
| Integrin alpha-IIb | 1 | 0 | 0 | 1 |
| Cytochrome P450 2C9 | 0 | 1 | 0 | 1 |
| Pleiotropic ABC efflux transporter of multiple drugs | 0 | 1 | 0 | 2 |
| Histamine H2 receptor | 1 | 0 | 0 | 1 |
| D(1A) dopamine receptor | 1 | 0 | 0 | 1 |
| Cytochrome P450 2J2 | 0 | 1 | 0 | 1 |
| Aldehyde oxidase | 0 | 1 | 0 | 1 |
| Aldehyde oxidase 1 | 0 | 1 | 0 | 1 |
| Rap guanine nucleotide exchange factor 4 | 1 | 0 | 0 | 1 |
| Ataxin-2 | 2 | 0 | 0 | 2 |
| Aldehyde oxidase 1 | 0 | 1 | 0 | 1 |
| thioredoxin reductase | 1 | 0 | 0 | 1 |
| Solute carrier family 22 member 2 | 0 | 1 | 0 | 1 |
| Voltage-dependent L-type calcium channel subunit alpha-1F | 0 | 1 | 0 | 1 |
| Albumin | 0 | 0 | 1 | 1 |
| Cytochrome P450 2D6 | 0 | 1 | 0 | 1 |
| Beta-1 adrenergic receptor | 0 | 1 | 0 | 1 |
| Glycine receptor subunit alpha-1 | 0 | 0 | 1 | 1 |
| Sodium-dependent dopamine transporter | 0 | 2 | 0 | 2 |
| Histamine H2 receptor | 0 | 2 | 0 | 2 |
| 5-hydroxytryptamine receptor 1B | 0 | 2 | 0 | 2 |
| 5-hydroxytryptamine receptor 7 | 0 | 1 | 0 | 1 |
| 5-hydroxytryptamine receptor 2C | 0 | 1 | 0 | 1 |
| 5-hydroxytryptamine receptor 2A | 0 | 1 | 0 | 1 |
| D(2) dopamine receptor | 0 | 1 | 0 | 1 |
| Voltage-dependent L-type calcium channel subunit alpha-1D | 0 | 1 | 0 | 1 |
| 5-hydroxytryptamine receptor 2B | 0 | 1 | 0 | 1 |
| Voltage-dependent L-type calcium channel subunit alpha-1S | 0 | 1 | 0 | 1 |
| Voltage-dependent L-type calcium channel subunit alpha-1C | 0 | 1 | 0 | 1 |
| Sodium channel protein type 5 subunit alpha | 0 | 1 | 0 | 1 |
| 5-hydroxytryptamine receptor 1A | 0 | 1 | 0 | 1 |
| Multidrug and toxin extrusion protein 2 | 0 | 1 | 0 | 1 |
| Multidrug and toxin extrusion protein 1 | 0 | 1 | 0 | 1 |
| Histamine H3 receptor | 0 | 1 | 0 | 1 |
| thioredoxin glutathione reductase | 1 | 0 | 0 | 1 |
| arylsulfatase A | 1 | 0 | 0 | 1 |
| Aspartate aminotransferase, cytoplasmic | 0 | 1 | 0 | 1 |
| ATPase family AAA domain-containing protein 5 | 1 | 0 | 0 | 1 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |